Medicenna Therapeutics Corp.
No enriched coverage for $MDNAF in the last 7 days.
No SEC Form 4 filings for $MDNAF in the last 30 days.
See all $MDNAF insider activity →Medicenna Therapeutics (MDNA) will present Phase 1/2 data for MDNA11 at SITC 2026, showing activity in biomarker-enriched GI cancers, including ICI-refractory cases. The presentation highlights monotherapy and combination therapy results.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the results of its annual general and special meeting of shareholders. All director nominees were elected with over 97% votes. Shareholders approved the re-appointment of MNP LLP as auditor and a potential share consolidation to meet U.S. exchange listing requirements. The consolidation ratio and implementation are yet to be determined.
Medicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.
Recent MDNAF coverage spans corporate actions and financial news.
Medicenna Therapeutics (MDNA) will present Phase 1/2 data for MDNA11 at SITC 2026, showing activity in biomarker-enriched GI cancers, including ICI-refractory cases. The presentation highlights monotherapy and combination therapy results.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the results of its annual general and special meeting of shareholders. All director nominees were elected with over 97% votes. Shareholders approved the re-appointment of MNP LLP as auditor and a potential share consolidation to meet U.S. exchange listing requirements. The consolidation ratio and implementation are yet to be determined.
Medicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.
AlphAI scores every news story that mentions MDNAF with an AI model for sentiment and relevance, and aggregates insider trades from Medicenna Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medicenna Therapeutics (MDNA) will present Phase 1/2 data for MDNA11 at SITC 2026, showing activity in biomarker-enriched GI cancers, including ICI-refractory cases. The presentation highlights monotherapy and combination therapy results.
2 min readMedicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the results of its annual general and special meeting of shareholders. All director nominees were elected with over 97% votes. Shareholders approved the re-appointment of MNP LLP as auditor and a potential share consolidation to meet U.S. exchange listing requirements. The consolidation ratio and implementation are yet to be determined.
2 min readMedicenna Therapeutics shareholders approved a reverse share split, with a ratio ranging from 1-for-2 to 1-for-20, at the board's discretion. The move aims to support a potential U.S. exchange listing. The company also elected directors and re-appointed MNP LLP as auditor.
1 min read
